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There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posa-
conazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections.
In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents.
We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are
involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either
healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the
specific interactions.
Azole antifungal drugs exhibit a wide range and variety of drug-
drug interactions. They are a substrate for and inhibitors of
cytochrome P450 (CYP450) enzymes, as well as inhibitors of
membrane transporters such as P-glycoprotein (P-gP). The in-
hibition or induction of CYP450 enzymes may alter the phar-
macokinetic profile of the drugs involved and can thus affect
both interacting agents. This type of interaction should be
avoided whenever possible, because it can lead to either over-
dosing or underdosing of both drugs, leading to toxicity or to
loss of efficacy, respectively. The risk of this type of pharma-
cokinetic interaction occurring between an azole antifungal
drug and other drug classes can differ, depending on the in-
dividual drugs involved, even for drugs within the same class.
METHODS
A PubMed search of peer-reviewed journals and review articles
was performed using the keywords “antifungal,” “pharmaco-
kinetics,” “metabolism,” “drug interactions,” and the names of
the individual antifungal drugs. Only drug-drug interactions
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studied clinically are detailed in this review, because the clinical
importance of theoretical interactions cannot be properly as-
sessed. The drug-drug interactions were tabulated according to
risk category, with the most relevant category mentioned first.
Within each category, the interacting agent is the primary de-
terminant. Advice on how to cope with specific interactions
has been provided as clearly as possible.
The prediction of metabolic drug-drug interactions in hu-
mans from in vitro investigations or studies in laboratory an-
imals is not straightforward [1, 2]. Only human studies were
considered for review, because, with respect to animals, sub-
strate specificities and inhibitor potencies for the enzymes me-
diating drug biotransformation are not conserved between
species.
PHARMACOKINETICS OF AZOLE ANTIFUNGAL
DRUGS
Fluconazole. After oral administration, fluconazole is rapidly
and fully (bioavailability 190%) absorbed, with a time to max-
imum absorption of 0.5–1.5 h after intake of the drug [3].
Tablets are bioequivalent to oral suspension and rectal sup-
positories [3, 4]. Fluconazole has a protein binding of 11%–
12%, but this can increase up to 23% in patients with chronic
renal failure [5]. The volume of distribution in adults is 0.56–
0.82 L/kg [3, 6]. Elimination is primarily by renal excretion,
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the drug being metabolized [7, 8]. The elimination half-life for
adults is ∼30 h but is markedly reduced in children (15–25 h)
[3]. For patients with renal failure, the maintenance dose has
to be reduced by 50% [3]. For patients requiring hemodialysis,
1 full dose (100%) should be administered after every dialysis
session [3].
Itraconazole. The oral formulation of itraconazole consists
of capsules and an oral solution. Capsules have a less favorable
pharmacokinetic profile, compared with the oral solution [9].
Systemic bioavailability of itraconazole oral solution is ∼55%
and is optimized under fasting conditions [10, 11]. Itraconazole
is highly protein bound (199%) [12] and penetrates extensively
into human tissue [13], but it has limited penetration into the
cerebrospinal fluid [14]. Itraconazole is extensively metabolized
by the liver, predominantly by the CYP3A4 isoenzyme system,
and is known to undergo enterohepatic recirculation [15]. Hy-
droxy-itraconazole is the major metabolite and shows an an-
tifungal activity equal to that of the parent compound. Me-
tabolites of itraconazole are excreted into the urine (40% of
metabolites) and bile (55% of metabolites). Itraconazole is a
substrate for and an inhibitor of CYP3A4 and an inhibitor of
P-gP [10, 16].
Voriconazole. Voriconazole, given orally, is rapidly and al-
most fully absorbed (oral bioavailability 190%), with a maxi-
mum plasma concentration (Cmax) being achieved ∼2 h after
administration under fasting conditions [17]. The volume of
distribution of voriconazole is estimated to be ∼4.6 L/kg, with
a plasma protein binding of ∼58% [18]. Voriconazole is ex-
tensively distributed into tissues and penetrates well into cer-
ebrospinal fluid [19, 20] and into vitreous and aqueous humors
[21–23]. The steady state plasma concentrations of voriconazole
in healthy volunteers are reached after 5–7 days of treatment
but can be reached after 24 h by giving a loading dose [24–
26]. Voriconazole exhibits nonlinear pharmacokinetics, with a
Cmax and an area under the concentration-time curve (AUC)
that increase more than proportionally with an increase in dose,
possibly because of saturation of the hepatic metabolism of the
drug. The major redundant metabolic pathway involves
CYP2C19, with CYP2C9 and CYP3A4 being involved to a much
lesser extent. The major metabolite of voriconazole possesses
no antifungal activity. Voriconazole is an inhibitor of CYP2C9,
CYP2C19, and CYP3A4. The drug’s metabolites are primarily
excreted in the urine [18]. The apparent serum half-life of
voriconazole is ∼6 h, but it can become longer with a higher
dosage [27].
Posaconazole. Posaconazole is only available as an oral for-
mulation. Like itraconazole, posaconazole is absorbed slowly,
with a time to median maximum absorption of 5 h, and is also
strongly bound to plasma proteins (198%). The volume of
distribution varies considerably, and steady state is reached after
a period of 7–10 days [28–31]. Administration of 50–800 mg
to healthy volunteers resulted in a linear pharmacokinetic pro-
file [29], and doses of 1800 mg showed no marked increase in
total exposure. Administration of posaconazole in 2 or 4 di-
vided daily doses leads to a 2-fold or 3-fold increase in exposure,
respectively, compared with administration of 1 daily dose. Po-
saconazole is metabolized by a phase II reaction (uridine di-
phosphate–glucuronosyltransferase 1A4 enzyme system) and
converted into a nonactive metabolite [32, 33]. Approximately
78% of the drug is recovered in fecal samples [33], and most
of the metabolites are excreted into the urine with an elimi-
nation half-life of the parent compound of ∼35 h (range, 20–
66 h) [29]. Posaconazole is a substrate for P-gP in vitro.
MECHANISMS OF DRUG-DRUG INTERACTION
In general, pharmacokinetic interactions occur at the level of
drug absorption, distribution, excretion, and metabolism, with
the frequent involvement of the CYP450 metabolizing enzyme
system and drug transporters such as P-gP (figure 1). The
results of these interactions can be a decrease or an increase in
exposure to both interacting drugs, which can in turn lead to
reduced efficacy or increased toxicity, respectively. The mech-
anisms involved in pharmacokinetic drug-drug interactions are
outlined in the following sections.
PHARMACOKINETIC INTERACTIONS
Drug Absorption
All 4 antifungal drugs (i.e., fluconazole, itraconazole, posacon-
azole, and voriconazole) discussed in this review can be given
orally and require absorption through the mucous membranes
of the gastrointestinal tract; therefore, a change in plasma con-
centrations can be the result of incomplete drug absorption.
Drug absorption and, thus, the pharmacokinetic profile of a
drug can be substantially influenced by gastric pH or by the
presence of food.
Effect of food on the absorption of azoles. The pharma-
cokinetics and bioavailability of fluconazole are not affected by
food. The mean bioavailability of itraconazole oral solution
under steady state conditions was 43% higher for those who
fasted than for those who did not [34]. Single and multiple
oral doses of voriconazole with food lowered the bioavailability
by ∼22% and delayed absorption, compared with single and
multiple oral doses of voriconazole without food [35]. Ad-
ministration of voriconazole with a high-fat meal reduced the
mean Cmax and AUC by 34% and 24%, respectively [18]. For
this reason, oral administration is recommended either 1 h
before or 1 h after meals. Posaconazole absorption is strongly
affected by the presence and composition of food. The mean
AUC and Cmax values increased by ∼400% when posaconazole
was administered with a high-fat meal, compared with when
it was administered under fasting conditions [36]. The admin-
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Figure 1. Involvement of cytochrome P450 enzymes and P-glycoprotein (P-gP) in the metabolism of azole antifungal drugs (adapted from Dr. Peter
Donnelly).
sure, resulting in a 2.6-fold increase in the AUC and a 3.0-fold
increase in the Cmax, relative to the administration of posacon-
azole under fasting conditions [37, 38]. The coadministration
of posaconazole with a nutritional supplement resulted in a
3.4-fold increase in the Cmax and a 6-fold increase in the AUC,
relative to the administration of posaconazole under fasting
conditions [39]. The daily dose of posaconazole should be di-
vided for malnourished patients (e.g., 200 mg 4 times a day).
Effect of gastric pH and acid-reducing agents on the ab-
sorption of azoles. The absorption of fluconazole is not af-
fected by drugs that increase gastric pH [40]. The concomitant
administration of itraconazole and proton pump inhibitors
(e.g., omeprazole) or H2 receptor antagonists (e.g., famotidine
and ranitidine) leads to impaired absorption of itraconazole,
resulting in a decrease in exposure [10].
The absorption of voriconazole is not markedly influenced
by antacids or proton pump inhibitors, although the mean Cmax
and AUC values of voriconazole are increased by 15% and 41%
when coadministered with omeprazole, because of the inhi-
bition of plasma clearance of voriconazole [41]. The Cmax and
AUC values of posaconazole were both reduced by 39% when
coadministered with cimetidine (400 mg twice daily), possibly
as a result of decreased gastric acid production. The effects of
proton pump inhibitors (e.g., esomeprazole) that may suppress
gastric acidity for several hours have only been presented in
abstract form [36]. The concomitant administration of posa-
conazole with esomeprazole resulted in a 33% decrease in po-
saconazole exposure [28].
Not only the gastric pH but also the integrity of the gastro-
intestinal tract may be important factors for the absorption of
antifungal drugs. For instance, posaconazole absorption ap-
peared to be reduced in patients with grade 1 or grade 2 mu-
cositis, compared with patients without mucositis (AUC for
400 mg of posaconazole twice daily, 4.54 vs. 8.85 mg  h/L)
[42].
Metabolism
Drug metabolism mainly occurs in the liver, where 2 types of
reactions occur. Most drugs are metabolized by phase I reac-
tions that involve oxidation, reduction, and hydrolysis prin-
cipally involving the CYP450 enzymes. In contrast, phase II
reactions are not mediated by CYP enzymes but involve the
conjugation of the drugs. Drugs can be substrates, inducers, or
inhibitors. Substrates are moieties that undergo metabolism by
1 enzyme. Enzyme induction can lead to either increased
drug exposure (in the case of a prodrug) and decreased drug
exposure, with subsequent decreased effect. It may take from
up to a few days to 2–3 weeks for enzyme induction to reach
its full extent. Enzyme inhibition, on the other hand, is in-
stantaneous and is dependent on the dose of the drug.
Effect of Azole Antifungal Drugs on Comedication
All azoles inhibit the CYP3A4 isoenzyme (figure 1). In humans,
CYP3A comprises the largest fraction of the total CYP content
and is responsible for the metabolism of a broad range of drugs.
Furthermore, CYP3A4 is involved in presystemic metabolism
in the gastrointestinal tract, influencing the absorption of
CYP3A substrates. The inhibitory potential of each of the azole
antifungal drugs varies greatly: itraconazole and posaconazole
are more-potent inhibitors of CYP3A4 than are fluconazole or
voriconazole. In addition to CYP3A4, fluconazole and vori-
conazole are also strong noncompetitive or mixed-type inhib-
itors of CYP2C9 and CYP2C19 [27, 43, 44]. The clinical rel-
evance of the pharmacokinetic interactions depends on the CYP
isoform that metabolizes the coadministered drug and on the
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Effect of Comedication on Azole Antifungal Drugs
Itraconazole and voriconazole are metabolized by the liver via
phase I reactions. Voriconazole is a substrate for CYP2C19 and,
to a lesser extent, for CYP2C9 and CYP3A4 [45, 46]. Itracon-
azole is predominantly metabolized by CYP3A4 and is the only
azole antifungal drug with an active metabolite [13, 15]. Flu-
conazole is mainly excreted unchanged into the urine, and
hepatic metabolism via CYP3A4 accounts for only 11% of the
total drug excreted [6]. It is therefore unlikely that the inter-
actions that influence the pharmacokinetic profile of flucona-
zole originated from this enzyme system. Posaconazole metab-
olism involves phase II reactions (i.e., glucuronidation of the
drug) [32]. The drugs that influence phase II enzyme systems,
such as lopinavir plus ritonavir [47], can exert a change in the
pharmacokinetic profile of the azole drug involved, leading to
increased or decreased exposure.
Genetic Polymorphism of CYP450 Enzyme Systems
All enzymes involved in the metabolism of azole antifungal
drugs are known to have multiple polymorphisms that divide
the population into poor metabolizers and extensive metabol-
izers. Patients who are homozygous or heterozygous poor me-
tabolizers have a limited enzymatic capacity for the isoenzyme,
which leads to a lower metabolic turnover of the drug involved
and, thus, higher exposure. Polymorphisms of CYP2C9 and
CYP2C19 may play a clinically relevant role, whereas poly-
morphisms of CYP3A4 are not considered clinically relevant.
In homozygous poor metabolizers of CYP2C19, the Cmax and
AUC values of voriconazole are 2–5 times higher than those
values in extensive metabolizers [48]. The CYP2C9 genotypic
variation does not significantly influence the exposure to vor-
iconazole, because only a small fraction of the drug is metab-
olized through this enzymatic pathway [49]. The prevalence of
variations in the gene sequence differs by race, with 20%–30%
of Asian persons and 2%–3% of white persons being homo-
zygous poor metabolizers of CYP2C19 [50]. Determining the
CYP2C19 genotype before initiation of therapy may predict
possible toxicity; Asian patients might especially benefit from
this approach. A cost-benefit analysis should be performed be-
fore using this approach in general practice. We do not rec-
ommend determining genotype before initiation of therapy,
because the monitoring of plasma concentrations and clinical
signs provide a better basis for management.
Drug Transporters
Active transporters, such as P-gP, organic anion-transporting
polypeptides (OATPs), and breast cancer resistant protein
(BCRP), play an important role in drug-drug interactions by
regulating the access of drugs to the drug-metabolizing enzymes
and by controlling drug concentrations in enterocytes and he-
patocytes. Thus, the contribution of efflux transporters in drug-
drug interactions cannot be excluded [16, 51]; however, there
is a lack of convincing data on the clinical relevance of drug
transporters.
P-gP. P-gP acts as an energy-dependent efflux pump that
exports substrates out of the cell and is an important molecular
determinant of oral bioavailability, brain penetration, and treat-
ment resistance to several therapeutically used drugs. The mod-
ulation of the P-gP function may play a significant role in drug-
drug interactions. Two azole antifungal drugs—itraconazole
and posaconazole—are substrates for and inhibitors of P-gP of
the multidrug resistance–1 gene [16, 28]. In vivo, no concrete
relationship between azole antifungal drugs and P-gP has been
established [51].
Other transporter systems. The OATP 1B1 is a multispecific
carrier capable of bidirectional transportation across the sinu-
soidal liver membrane [52]. For instance, atorvastatin is subject
to cellular membrane transport by OATP 1B1 and P-gP. It is
suggested that itraconazole might block the transportation of
atorvastatin because of the inhibition of the OATP 1B1 enzyme
system [53]. The exact role of OATP, however, has not been
established, and thus, its specific role in drug-drug interactions
with selected substrates and inhibitors, such as itraconazole, re-
mains unclear and requires further investigation.
The human BRCP belongs to the OATP-binding cassette
transporter family. The BCRP does not seem to be inhibited
by fluconazole or voriconazole. A simulation model has dem-
onstrated that it is highly likely that the BCRP is inhibited by
itraconazole [54]. In vivo, no relationship between azole an-
tifungal drugs and the BCRP has been established.
RENAL EXCRETION
Drug interactions based on alterations in renal elimination
mainly involve changes in tubular secretion or changes in kid-
ney function. Drugs that use the same active transportation
system in the kidney tubules can compete for this excretory
system. The 2 drugs excreted by the kidneys are fluconazole
and hydroxy-itraconazole. There have been no reports to date
that have shown that impaired renal function caused by neph-
rotoxic drugs such as cyclosporine or gentamicin has led to
increased toxicity of fluconazole or hydroxyl-itraconazole as a
result of increased exposure.
PREDICTION OF DRUG-DRUG INTERACTIONS
Drug-drug interactions can cause many clinical problems. Ide-
ally, comprehensive information should be available before a
new drug completes the registration process. Because we aim
for the maximum attainable therapeutic effect when treating
invasive fungal disease, it is important to be aware of the mech-
anisms, whether theoretical or proven, behind drug-drug in-
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cilitate rapid monitoring for interactions, thereby assisting in
the clinical decision-making process.
Therapeutic drug monitoring. A drug-drug interaction is
never straightforward, because not all patients will be effected
to the same degree when they experience a drug-drug inter-
action. Therapeutic drug monitoring is an important tool for
identifying the extent of the interaction and may help resolve
actual and potential problems. Therapeutic drug monitoring
can be used to guide dosing and to optimize therapy to prevent
subtherapeutic effects or toxicity [55].
PRACTICAL ISSUES FOR USE OF THE DRUG-
INTERACTION TABLE
Our drug-interaction table, which has a risk-ranking order of
categories adapted from the UptoDate Lexi-Interact Tool [56]
(table 1), provides an overview of drug-drug interactions pub-
lished in peer-reviewed journals. The interactions that are most
severe are listed first. This type of grading system helps the
clinician to judge which drug combinations should be avoided
and which drug combinations can be used safely. Futhermore,
we have defined 9 areas of study that we consider to be nec-
essary to review before making a judgement on the drug-drug
interaction. In one area of study, various authors have provided
recommendations on how to deal with the specific drug-drug
interactions. Both the risk ranking and the recommendations
reflect the opinions of the authors of the present article and
are based on the interpretation of (multiple) studies and gath-
ered information. Our recommendations may therefore differ
slightly from the recommendations of the authors of the studies
cited.
CONSIDERATIONS
We aimed to provide a comprehensive review of the phar-
macokinetic interactions of azole antifungal drugs with other
coadministered agents in the treatment of invasive fungal dis-
eases. New information is emerging rapidly, and thus, this re-
view is by its very nature incomplete. Awareness of the mech-
anisms involved in these interactions is pivotal for the op-
timization of treatment of patients requiring antifungal ther-
apy. For the clinical interpretation, it should be kept in mind
that much of the data presented in our review are from studies
of healthy volunteers or a limited number of patients, and the
clinical setting may therefore differ from the controlled setting
of an interaction study. Drug-drug interactions do not only
occur when therapy is initiated; they can also become evident
after the drug therapy is stopped, particularly if the agent in
question is an enzyme inducer, because this might lead to toxic
concentrations.
Therapeutic drug monitoring is a valuable tool for assessing
the effect of a drug-drug interaction for both the antifungal
azole drug and, if possible, the coadministered drug. To perform
therapeutic drug monitoring, a validated analytical method has
to be available to determine whole blood or plasma concen-
trations. Assays have to be validated to ensure accuracy and
precision. The measurement of samples can be done by in-
house laboratory technicians, if facilities are available, or sent
to reference laboratories with validated assays. The shorter the
turnaround time (for instance, within 48 h), the better (for
prompt patient management). Interpretation of the results can
be performed by a clinical pharmacist and/or pharmacologist
or by another health care professional who is familiar with
therapeutic drug monitoring. Finally, addressing the problem
of drug-drug interactions is a multidisciplinary task, with the
goal of minimizing unwanted adverse effects while optimizing
patient care.
Acknowledgments
We thank Dr. Peter Donnelly for his thoughtful review of this article.
Potential conflicts of interest. All authors: no conflicts.
References
1. Eagling VA, Tjia JF, Back DJ. Differential selectivity of cytochrome
P450 inhibitors against probe substrates in human and rat liver mi-
crosomes. Br J Clin Pharmacol 1998; 45:107–14.
2. Guengerich FP. Comparisons of catalytic selectivity of cytochrome
P450 subfamily enzymes from different species. Chem Biol Interact
1997; 106:161–82.
3. US Food and Drug Administration (FDA). Center for Drug Evalu-
ation and Research. Drugs@FDA: FDA approved drug products. DI-
FLUCAN. Available at: http://www.accessdata.fda.gov/scripts/cder/
drugsatfda/index.cfm?fuseactionpSearch.Overview&DrugNamep
DIFLUCAN. Accessed 7 January 2008.
4. Pfaff G, Zimmermann T, Lach P, Yeates R, Simon G, Wildfeuer A.
Pharmacokinetics and tolerance of fluconazole suppositories in
healthy volunteers. Arzneimittelforschung 1993; 43:391–5.
5. Buijk SL, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining
HA. Pharmacokinetics of sequential intravenous and enteral flucon-
azole in critically ill surgical patients with invasive mycoses and com-
promised gastro-intestinal function. Intensive Care Med 2001; 27:
115–21.
6. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of
UK-49,858, a metabolically stable triazole antifungal drug, in animals
and humans. Antimicrob Agents Chemother 1985; 28:648–53.
7. Dudley MN. Clinical pharmacology of fluconazole. Pharmacotherapy
1990; 10(6 Pt 3):S141–5.
8. Foulds G, Wajszczuk C, Weidler DJ, Garg DJ, Gibson P. Steady state
parenteral kinetics of fluconazole in man. Ann N Y Acad Sci 1988;
544:427–30.
9. de Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001;
61(Suppl 1):27–37.
10. US Food and Drug Administration (FDA). Center for Drug Evalu-
ation and Research. Drugs@FDA: FDA approved drug products.
Search results for “sporanox.” Available at: http://www.accessdata
.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 7 January 2008.
11. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability
of itraconazole in hydroxypropyl-b-cyclodextrin solution versus cap-
sules in healthy volunteers. Antimicrob Agents Chemother 1998; 42:
1862–5.
12. Arredondo G, Martinez-Jorda R, Calvo R, Aguirre C, Suarez E. Protein
binding of itraconazole and fluconazole in patients with chronic renal
failure. Int J Clin Pharmacol Ther 1994; 32:361–4.











1454 • CID 2009:48 (15 May) • REVIEWS OF ANTI-INFECTIVE AGENTS
and pharmacokinetic properties, and therapeutic use in superficial
and systemic mycoses. Drugs 1989; 37:310–44.
14. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole ther-
apy for chronic coccidioidal meningitis. Ann Intern Med 1990; 112:
108–12.
15. Bailey EM, Krakovsky DJ, Rybak MJ. The triazole antifungal agents:
a review of itraconazole and fluconazole. Pharmacotherapy 1990; 10:
146–53.
16. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction
of common azole antifungals with P glycoprotein. Antimicrob Agents
Chemother 2002; 46:160–5.
17. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Klei-
nermans D. Pharmacokinetics and safety of voriconazole following
intravenous- to oral-dose escalation regimens. Antimicrob Agents
Chemother 2002; 46:2546–53.
18. European Medicines Agency (EMEA). EPARs for authorised medici-
nal products for human use. Vfend. Available at: http://www.emea
.europa.eu/htms/human/epar/v.htm. Accessed 7 January 2008.
19. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cer-
ebrospinal fluid and brain tissue of guinea pigs and immunocom-
promised patients. Clin Infect Dis 2003; 37:728–32.
20. Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus
meningitis: diagnosis by non-culture-based microbiological methods
and management. J Clin Microbiol 1999; 37:1186–9.
21. Nulens E, Eggink C, Rijs AJ, Wesseling P, Verweij PE. Keratitis caused
by Scedosporium apiospermum successfully treated with a cornea trans-
plant and voriconazole. J Clin Microbiol 2003; 41:2261–4.
22. Klont RR, Eggink CA, Rijs AJ, Wesseling P, Verweij PE. Successful
treatment of Fusarium keratitis with cornea transplantation and top-
ical and systemic voriconazole. Clin Infect Dis 2005; 40:e110–2.
23. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous,
aqueous, and plasma concentration of orally administered voricon-
azole in humans. Arch Ophthalmol 2004; 122:42–7.
24. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharma-
codynamic profile of voriconazole. Clin Pharmacokinet 2006; 45:
649–63.
25. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole,
a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br
J Clin Pharmacol 2003; 56(Suppl 1):10–6.
26. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D.
The pharmacokinetics and safety of intravenous voriconazole—a
novel wide-spectrum antifungal agent. Br J Clin Pharmacol 2003;
56(Suppl 1):2–9.
27. Hyland R, Jones BC, Smith DA. Identification of the cytochrome
P450 enzymes involved in the N-oxidation of voriconazole. Drug
Metab Dispos 2003; 31:540–7.
28. European Medicines Agency (EMEA). EPARs for authorised medicinal
products for human use. Noxafil. Available at: http://www.emea
.europa.eu/htms/human/epar/n.htm. Accessed 7 January 2008.
29. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics,
safety, and tolerability of oral posaconazole administered in single
and multiple doses in healthy adults. Antimicrob Agents Chemother
2003; 47:2788–95.
30. Keating GM. Posaconazole. Drugs 2005; 65:1553–67.
31. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender,
and race/ethnicity on the pharmacokinetics of posaconazole in healthy
volunteers. Antimicrob Agents Chemother 2007; 51:495–502.
32. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-
glucuronosyltransferase enzyme(s) responsible for the glucuronida-
tion of posaconazole (Noxafil). Drug Metab Dispos 2004; 32:267–71.
33. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney
R. Disposition of posaconazole following single-dose oral adminis-
tration in healthy subjects. Antimicrob Agents Chemother 2004; 48:
3543–51.
34. Barone JA, Moskovitz BL, Guarnieri J, et al. Food interaction and
steady-state pharmacokinetics of itraconazole oral solution in healthy
volunteers. Pharmacotherapy 1998; 18:295–301.
35. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect
of food on the pharmacokinetics of multiple-dose oral voriconazole.
Br J Clin Pharmacol 2003; 56(Suppl 1):17–23.
36. Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the
pharmacokinetic properties of oral and intravenous midazolam: a
phase I, randomized, open-label, crossover study in healthy volun-
teers. Clin Ther 2009; 31:286–98.
37. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of
food on the relative bioavailability of two oral formulations of po-
saconazole in healthy adults. Br J Clin Pharmacol 2004; 57:218–22.
38. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of
posaconazole coadministered with antacid in fasting or nonfasting
healthy men. Antimicrob Agents Chemother 2004; 48:804–8.
39. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional
supplement on posaconazole pharmacokinetics following oral ad-
ministration to healthy volunteers. Antimicrob Agents Chemother
2006; 50:1881–3.
40. Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH
and the bioavailability of fluconazole and ketoconazole. Ann Intern
Med 1991; 114:755–7.
41. Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-
state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003;
56(Suppl 1):56–61.
42. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics
and safety of oral posaconazole in neutropenic stem cell transplant
recipients. Antimicrob Agents Chemother 2006; 50:1993–9.
43. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole. II. A
metabolically based drug interaction: in vivo studies. Drug Metab
Dispos 1996; 24:422–8.
44. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal
agent. Clin Infect Dis 2003; 36:630–7.
45. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A.
Coadministration of voriconazole and phenytoin: pharmacokinetic
interaction, safety, and toleration. Br J Clin Pharmacol 2003; 56(Suppl
1):37–44.
46. Geist MJ, Egerer G, Burhenne J, Riedel KD, Mikus G. Induction of
voriconazole metabolism by rifampin in a patient with acute myeloid
leukemia: importance of interdisciplinary communication to prevent
treatment errors with complex medications. Antimicrob Agents Che-
mother 2007; 51:3455–6.
47. van der Lee MJ, Dawood L, ter Hofstede HJ, et al. Lopinavir/ritonavir
reduces lamotrigine plasma concentrations in healthy subjects. Clin
Pharmacol Ther 2006; 80:159–68.
48. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima
M. Pharmacokinetics of voriconazole and cytochrome P450 2C19
genetic status. Clin Pharmacol Ther 2004; 75:587–8.
49. Geist MJ, Egerer G, Burhenne J, Mikus G. Safety of voriconazole in
a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob Agents
Chemother 2006; 50:3227–8.
50. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of ome-
prazole correlates with S-mephenytoin metabolism: a population
study. Clin Pharmacol Ther 1995; 57:662–9.
51. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the
antifungal agents on oxidative drug metabolism: clinical relevance.
Clin Pharmacokinet 2000; 38:111–80.
52. Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute
transport: a role for intracellular glutathione. Mol Pharmacol 2000;
58:335–40.
53. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Phar-
macokinet 2003; 42:1141–60.
54. Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents
with the human breast cancer resistance protein (BCRP). J Pharm
Sci 2007; 96:3226–35.
55. Bru¨ggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug
monitoring of voriconazole. Ther Drug Monit 2008; 30:403–11.
56. UptoDate. Lexi-Interact Online. Available at: http://www.uptodate











REVIEWS OF ANTI-INFECTIVE AGENTS • CID 2009:48 (15 May) • 1455
57. Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced
oral itraconazole bioavailability by antacid suspension. J Clin Pharm
Ther 2005; 30:201–6.
58. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles
with rifampin, phenytoin, and carbamazepine: in vitro and clinical
observations. Clin Infect Dis 1992; 14:165–74.
59. May DB, Drew RH, Yedinak KC, Bartlett JA. Effect of simultaneous
didanosine administration on itraconazole absorption in healthy vol-
unteers. Pharmacotherapy 1994; 14:509–13.
60. Naef R, Schmid C, Hofer M, Minder S, Speich R, Boehler A. Itra-
conazole comedication increases systemic levels of inhaled fluticasone
in lung transplant recipients. Respiration 2007; 74:418–22.
61. Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M. Grapefruit
juice decreases the systemic availability of itraconazole capsules in
healthy volunteers. Ther Drug Monit 1999; 21:304–9.
62. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma
concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther
1996; 60:54–61.
63. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole
on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Phar-
macol 1998; 46:49–53.
64. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the phar-
macokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54:159–61.
65. Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and
hydroxyitraconazole serum concentrations are reduced more than
tenfold by phenytoin. Clin Pharmacol Ther 1995; 58:617–24.
66. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction as-
sessment following concomitant administration of posaconazole and
phenytoin in healthy men. Curr Med Res Opin 2007; 23:1415–22.
67. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the phar-
macokinetics of posaconazole and rifabutin following co-administra-
tion to healthy men. Curr Med Res Opin 2007; 23:545–52.
68. Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the phar-
macokinetics of itraconazole in normal volunteers and AIDS patients.
Eur J Clin Pharmacol 1998; 54:155–8.
69. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus
coadministration after allogeneic hematopoietic stem cell transplan-
tation. Biol Blood Marrow Transplant 2006; 12:552–9.
70. Rengelshausen J, Banfield M, Riedel KD, et al. Opposite effects of
short-term and long-term St John’s wort intake on voriconazole phar-
macokinetics. Clin Pharmacol Ther 2005; 78:25–33.
71. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR.
Itraconazole affects single-dose terfenadine pharmacokinetics and car-
diac repolarization pharmacodynamics. J Clin Pharmacol 1993; 33:
1201–6.
72. Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time
interval on the interaction between itraconazole and triazolam. Clin
Pharmacol Ther 1996; 60:326–31.
73. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially
hazardous to patients receiving systemic antimycotics ketoconazole
or itraconazole. Clin Pharmacol Ther 1994; 56(6 Pt 1):601–7.
74. Ariffin H, Omar KZ, Ang EL, Shekhar K. Severe vincristine neuro-
toxicity with concomitant use of itraconazole. J Paediatr Child Health
2003; 39:638–9.
75. Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itracon-
azole-related increased vincristine neurotoxicity: case report and re-
view of literature. J Pediatr Hematol Oncol 2005; 27:389–92.
76. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced
neurotoxicity by itraconazole in the treatment of adult ALL. Ann
Hematol 1995; 71:311–2.
77. Gillies J, Hung KA, Fitzsimons E, Soutar R. Severe vincristine toxicity
in combination with itraconazole. Clin Lab Haematol 1998; 20:123–4.
78. Jeng MR, Feusner J. Itraconazole-enhanced vincristine neurotoxicity
in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol
2001; 18:137–42.
79. Kamaluddin M, McNally P, Breatnach F, et al. Potentiation of vin-
cristine toxicity by itraconazole in children with lymphoid malignan-
cies. Acta Paediatr 2001; 90:1204–7.
80. Murphy JA, Ross LM, Gibson BE. Vincristine toxicity in five children
with acute lymphoblastic leukaemia. Lancet 1995; 346:443.
81. Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S.
Vincristine-itraconazole interaction: cause for increasing concern. J
Pediatr Hematol Oncol 2002; 24:591.
82. Sathiapalan RK, El-Solh H. Enhanced vincristine neurotoxicity from
drug interactions: case report and review of literature. Pediatr He-
matol Oncol 2001; 18:543–6.
83. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT. The effect of
intravenous and oral fluconazole on the pharmacokinetics and
pharmacodynamics of intravenous alfentanil. Anesth Analg 1998; 87:
190–4.
84. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT.
Voriconazole, but not terbinafine, markedly reduces alfentanil clear-
ance and prolongs its half-life. Clin Pharmacol Ther 2006; 80:502–8.
85. Newberry DL, Bass SN, Mbanefo CO. A fluconazole/amitriptyline
drug interaction in three male adults. Clin Infect Dis 1997; 24:270–1.
86. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the
pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64:
58–65.
87. Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT. Plasma
concentrations of inhaled budesonide and its effects on plasma cor-
tisol are increased by the cytochrome P4503A4 inhibitor itraconazole.
Clin Pharmacol Ther 2002; 72:362–9.
88. Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S. Iatrogenic
adrenal insufficiency as a side-effect of combined treatment of itra-
conazole and budesonide. Eur Respir J 2002; 20:127–33.
89. Christensen J, Dupont E, Ostergaard K. Cabergoline plasma concen-
tration is increased during concomitant treatment with itraconazole.
Mov Disord 2002; 17:1360–2.
90. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole
increases but grapefruit juice greatly decreases plasma concentrations
of celiprolol. Clin Pharmacol Ther 2003; 73:192–8.
91. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ,
Matas AJ. Interaction between cyclosporine and fluconazole in renal
allograft recipients. Transplantation 1991; 51:1014–8.
92. Sud K, Singh B, Krishna VS, et al. Unpredictable cyclosporin–
fluconazole interaction in renal transplant recipients. Nephrol Dial
Transplant 1999; 14:1698–703.
93. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR.
Evaluation of the drug interaction between intravenous high-dose
fluconazole and cyclosporine or tacrolimus in bone marrow transplant
patients. Transplantation 1996; 61:1268–72.
94. Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, Nicolau
DP. Beneficial pharmacokinetic interaction between cyclosporine and
itraconazole in renal transplant recipients. Transplant Proc 2003; 35:
2873–7.
95. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic eval-
uation of the drug interaction between intravenous itraconazole and
intravenous tacrolimus or intravenous cyclosporin A in allogeneic
hematopoietic stem cell transplant recipients. Biol Blood Marrow
Transplant 2006; 12:325–34.
96. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S,
Mant TG. Effect of oral posaconazole on the pharmacokinetics of
cyclosporine and tacrolimus. Pharmacotherapy 2007; 27:825–34.
97. Romero AJ, Le PP, Nilsson LG, Wood N. Effect of voriconazole on
the pharmacokinetics of cyclosporine in renal transplant patients. Clin
Pharmacol Ther 2002; 71:226–34.
98. Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC.
Renal interaction between itraconazole and cimetidine. J Clin Phar-
macol 2004; 44:919–27.
99. Hynninen VV, Olkkola KT, Leino K, et al. Effect of voriconazole on












1456 • CID 2009:48 (15 May) • REVIEWS OF ANTI-INFECTIVE AGENTS
100. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal
clearance of digoxin. Ther Drug Monit 1997; 19:609–13.
101. Liu P, Foster G, Labadie RR, Gutierrez MJ, Sharma A. Pharmacoki-
netic interaction between voriconazole and efavirenz at steady state
in healthy male subjects. J Clin Pharmacol 2008; 48:73–84.
102. Damle B, Labadie R, Crownover P, Glue P. Pharmacokinetic inter-
actions of efavirenz and voriconazole in healthy volunteers. Br J Clin
Pharmacol 2008; 65:523–30.
103. Andrews E, Damle BD, Fang A, et al. Pharmacokinetics and tolera-
bility of voriconazole and a combination oral contraceptive co-ad-
ministered in healthy female subjects. Br J Clin Pharmacol 2008; 65:
531–9.
104. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases
plasma concentrations and effects of felodipine. Clin Pharmacol Ther
1997; 61:410–5.
105. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect
of fluconazole on plasma fluvastatin and pravastatin concentrations.
Eur J Clin Pharmacol 2000; 56:225–9.
106. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto
KT. Effects of fluconazole and fluvoxamine on the pharmacokinetics
and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001;
69:194–200.
107. Liu P, Foster G, Labadie R, Somoza E, Sharma A. Pharmacokinetic
interaction between voriconazole and methadone at steady state in pa-
tients on methadone therapy. Antimicrob Agents Chemother 2007; 51:
110–8.
108. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration
of fluconazole on the interaction between fluconazole and midazolam.
Eur J Clin Pharmacol 1997; 51:415–9.
109. Ahonen J, Olkkola KT, Takala A, Neuvonen PJ. Interaction between
fluconazole and midazolam in intensive care patients. Acta Anaes-
thesiol Scand 1999; 43:509–14.
110. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic
antimycotics, itraconazole and fluconazole, on the pharmacokinetics
and pharmacodynamics of intravenous and oral midazolam. Anesth
Analg 1996; 82:511–6.
111. Vanakoski J, Mattila MJ, Vainio P, Idanpaan-Heikkila JJ, Tornwall M.
150 mg fluconazole does not substantially increase the effects of 10
mg midazolam or the plasma midazolam concentrations in healthy
subjects. Int J Clin Pharmacol Ther 1995; 33:518–23.
112. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and ter-
binafine on the pharmacokinetics and pharmacodynamics of mida-
zolam in healthy volunteers. Br J Clin Pharmacol 1995; 40:270–2.
113. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under
the plasma concentration-time curve for oral midazolam is 400-fold
larger during treatment with itraconazole than with rifampicin. Eur
J Clin Pharmacol 1998; 54:53–8.
114. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided
in patients receiving the systemic antimycotics ketoconazole or itra-
conazole. Clin Pharmacol Ther 1994; 55:481–5.
115. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M.
Effect of posaconazole on cytochrome P450 enzymes: a randomized,
open-label, two-way crossover study. Eur J Pharm Sci 2004; 21:645–53.
116. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT.
Effect of voriconazole on the pharmacokinetics and pharmacodynam-
ics of intravenous and oral midazolam. Clin Pharmacol Ther 2006;
79:362–70.
117. Garazzino S, Tettoni M, Calcagno A, D’Avolio A, Bonora S, Di Perri
G. Ritonavir-dependent fluconazole boosting of nelfinavir: a report
of three cases. J Antimicrob Chemother 2006; 58:483–5.
118. Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the in-
teraction between itraconazole and nevirapine. Eur J Clin Pharmacol
2007; 63:451–6.
119. Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of flu-
conazole on the pharmacokinetics of omeprazole in healthy volun-
teers. Biopharm Drug Dispos 2002; 23:77–81.
120. Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on
the disposition of phenytoin. Clin Pharmacol Ther 1991; 49:420–5.
121. Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic
and safety profiles of voriconazole and ritonavir in healthy male sub-
jects. Antimicrob Agents Chemother 2007; 51:3617–26.
122. Mikus G, Schowel V, Drzewinska M, et al. Potent cytochrome P450
2C19 genotype-related interaction between voriconazole and the cy-
tochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;
80:126–35.
123. Cardiello PG, Samor T, Burger D, et al. Pharmacokinetics of lower
doses of saquinavir soft-gel caps (800 and 1200 mg twice daily)
boosted with itraconazole in HIV-1-positive patients. Antivir Ther
2003; 8:245–9.
124. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin
is very susceptible to interaction with the CYP3A4 inhibitor itracon-
azole. Clin Pharmacol Ther 1998;63:332–41.
125. Manez R, Martin M, Raman D, et al. Fluconazole therapy in transplant
recipients receiving FK506. Transplantation 1994; 57:1521–3.
126. Shitrit D, Ollech JE, Ollech A, et al. Itraconazole prophylaxis in lung
transplant recipients receiving tacrolimus (FK 506): efficacy and drug
interaction. J Heart Lung Transplant 2005; 24:2148–52.
127. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT.
Effect of voriconazole on the pharmacokinetics and pharmacody-
namics of zolpidem in healthy subjects. Br J Clin Pharmacol 2007;
63:116–20.
128. Yasui N, Kondo T, Otani K, et al. Effect of itraconazole on the single
oral dose pharmacokinetics and pharmacodynamics of alprazolam.
Psychopharmacology (Berl) 1998; 139:269–73.
129. Furukori H, Kondo T, Yasui N, et al. Effects of itraconazole on the
steady-state plasma concentrations of bromperidol and reduced brom-
peridol in schizophrenic patients. Psychopharmacology (Berl) 1999; 145:
189–92.
130. Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-re-
ceptor antagonists have no clinically significant effect on the steady-
state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003;
56(Suppl 1):51–5.
131. Auclair B, Berning SE, Huitt GA, Peloquin CA. Potential interaction
between itraconazole and clarithromycin. Pharmacotherapy 1999; 19:
1439–44.
132. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metab-
olism is affected by azole antifungals. Blood 2004; 103:1557–9.
133. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. The cytochrome P450
3A4 inhibitor itraconazole markedly increases the plasma concentra-
tions of dexamethasone and enhances its adrenal-suppressant effect.
Clin Pharmacol Ther 2000; 68:487–94.
134. Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT. Voricon-
azole and fluconazole increase the exposure to oral diazepam. Eur J
Clin Pharmacol 2007; 63:941–9.
135. Ahonen J, Olkkola KT, Neuvonen PJ. The effect of the antimycotic
itraconazole on the pharmacokinetics and pharmacodynamics of di-
azepam. Fundam Clin Pharmacol 1996; 10:314–8.
136. Araki K, Yasui-Furukori N, Fukasawa T, et al. Inhibition of the me-
tabolism of etizolam by itraconazole in humans: evidence for the
involvement of CYP3A4 in etizolam metabolism. Eur J Clin Phar-
macol 2004; 60:427–30.
137. Saari TI, Laine K, Neuvonen M, Neuvonen PJ, Olkkola KT. Effect of
voriconazole and fluconazole on the pharmacokinetics of intravenous
fentanyl. Eur J Clin Pharmacol 2008; 64:25–30.
138. Palkama VJ, Neuvonen PJ, Olkkola KT. The CYP 3A4 inhibitor itra-
conazole has no effect on the pharmacokinetics of i.v. fentanyl. Br J
Anaesth 1998; 81:598–600.
139. Park JY, Shon JH, Kim KA, et al. Combined effects of itraconazole
and CYP2D6*10 genetic polymorphism on the pharmacokinetics and
pharmacodynamics of haloperidol in healthy subjects. J Clin Psycho-
pharmacol 2006; 26:135–42.











REVIEWS OF ANTI-INFECTIVE AGENTS • CID 2009:48 (15 May) • 1457
voriconazole and fluconazole on the pharmacokinetics of s-(+)- and
R-()-Ibuprofen. Antimicrob Agents Chemother 2006; 50:1967–72.
141. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Back-
man JT. Itraconazole, gemfibrozil and their combination markedly
raise the plasma concentrations of loperamide. Eur J Clin Pharmacol
2006; 62:463–72.
142. Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the
pharmacokinetics of eprosartan and losartan in healthy male vol-
unteers. Clin Pharmacol Ther 1997; 62:417–25.
143. Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itra-
conazole decreases the metabolism of losartan to E-3174. Eur J Clin
Pharmacol 1998; 53:445–9.
144. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. Itraconazole decreases
the clearance and enhances the effects of intravenously administered
methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999;
85:29–32.
145. Masui T, Kusumi I, Takahashi Y, Koyama T. Effects of itraconazole
and tandospirone on the pharmacokinetics of perospirone. Ther Drug
Monit 2006; 28:73–5.
146. Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram,
itraconazole, grapefruit juice and erythromycin on the pharmacoki-
netics of quinidine. Br J Clin Pharmacol 1999; 48:829–38.
147. Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases
plasma concentrations of quinidine. Clin Pharmacol Ther 1997; 62:
510–7.
148. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gem-
fibrozil, itraconazole, and their combination on the pharmacokinetics
and pharmacodynamics of repaglinide: potentially hazardous inter-
action between gemfibrozil and repaglinide. Diabetologia 2003; 46:
347–51.
149. Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin
levels with concomitant fluconazole therapy in HIV-infected patients.
Ann Intern Med 1996; 124:573–6.
150. Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC.
Effects of fluconazole and clarithromycin on rifabutin and 25-O-
desacetylrifabutin pharmacokinetics. Antimicrob Agents Chemother
2000; 44:2170–2.
151. Jaruratanasirikul S, Kleepkaew A. Lack of effect of fluconazole on the
pharmacokinetics of rifampicin in AIDS patients. J Antimicrob Che-
mother 1996; 38:877–80.
152. Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul
S. Effect of rifampicin on the pharmacokinetics of fluconazole in
patients with AIDS. Clin Pharmacokinet 2004; 43:725–32.
153. Nicolau DP, Crowe HM, Nightingale CH, Quintiliani R. Rifampin-
fluconazole interaction in critically ill patients. Ann Pharmacother
1995; 29:994–6.
154. Jung SM, Kim KA, Cho HK, et al. Cytochrome P450 3A inhibitor
itraconazole affects plasma concentrations of risperidone and 9-hy-
droxyrisperidone in schizophrenic patients. Clin Pharmacol Ther
2005; 78:520–8.
155. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of clarith-
romycin and itraconazole on the pharmacokinetics of ropivacaine.
Pharmacol Toxicol 2001; 88:187–91.
156. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine,
enhances the effects of triazolam by inhibiting its metabolism. Br J
Clin Pharmacol 1996; 41:319–23.
157. Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the
extent of fluconazole-triazolam interaction. Br J Clin Pharmacol
1996; 42:465–70.
158. Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen K, Neuvonen PJ,
Laine K. Effect of terbinafine and voriconazole on the pharmacoki-
netics of the antidepressant venlafaxine. Clin Pharmacol Ther 2008;
83:342–8.
159. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole poten-
tiates warfarin-induced prothrombin time prolongation. Br J Clin
Pharmacol 2003; 56(Suppl 1):24–9.
160. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-admin-
istration and CYP2D6 genotype on the pharmacokinetics of the new
antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet 2005; 20:
55–64.
161. Lilja JJ, Backman JT, Neuvonen PJ. Effect of itraconazole on the
pharmacokinetics of atenolol. Basic Clin Pharmacol Toxicol 2005; 97:
395–8.
162. Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols
D. No clinically significant effect of erythromycin or azithromycin on
the pharmacokinetics of voriconazole in healthy male volunteers. Br
J Clin Pharmacol 2003; 56(Suppl 1):30–6.
163. Palkama VJ, Neuvonen PJ, Olkkola KT. Effect of itraconazole on the
pharmacokinetics of bupivacaine enantiomers in healthy volunteers.
Br J Anaesth 1999; 83:659–61.
164. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase
systemic exposure to busulfan in patients given bone marrow trans-
plantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo).
Anticancer Res 1996; 16:2083–8.
165. Winter HR, Trapnell CB, Slattery JT, et al. The effect of clarithromycin,
fluconazole, and rifabutin on sulfamethoxazole hydroxylamine for-
mation in individuals with human immunodeficiency virus infection
(AACTG 283). Clin Pharmacol Ther 2004; 76:313–22.
166. Damle B, Hess H, Kaul S, Knupp C. Absence of clinically relevant
drug interactions following simultaneous administration of didano-
sine-encapsulated, enteric-coated bead formulation with either itra-
conazole or fluconazole. Biopharm Drug Dispos 2002; 23:59–66.
167. Sinofsky FE, Pasquale SA. The effect of fluconazole on circulating
ethinyl estradiol levels in women taking oral contraceptives. Am J
Obstet Gynecol 1998; 178:300–4.
168. Hilbert J, Messig M, Kuye O, Friedman H. Evaluation of interaction
between fluconazole and an oral contraceptive in healthy women.
Obstet Gynecol 2001; 98:218–23.
169. Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population
pharmacokinetics of everolimus in de novo renal transplant patients:
impact of ethnicity and comedications. Clin Pharmacol Ther 2001;
70:247–54.
170. Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of single and
multiple doses of itraconazole on the pharmacokinetics of fexofen-
adine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006; 62:
372–6.
171. Shon JH, Yoon YR, Hong WS, et al. Effect of itraconazole on the
pharmacokinetics and pharmacodynamics of fexofenadine in relation
to the MDR1 genetic polymorphism. Clin Pharmacol Ther 2005; 78:
191–201.
172. Uno T, Shimizu M, Sugawara K, Tateishi T. Lack of dose-dependent
effects of itraconazole on the pharmacokinetic interaction with fex-
ofenadine. Drug Metab Dispos 2006; 34:1875–9.
173. Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug
interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Clin Pharmacokinet 2005; 44:1067–81.
174. Gubbins PO, McConnell SA, Gurley BJ, et al. Influence of grapefruit
juice on the systemic availability of itraconazole oral solution in
healthy adult volunteers. Pharmacotherapy 2004; 24:460–7.
175. Ouellet D, Bramson C, Roman D, et al. Effects of three cytochrome
P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the
pharmacokinetics of lasofoxifene. Br J Clin Pharmacol 2007; 63:59–66.
176. Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT. Effect of eryth-
romycin and itraconazole on the pharmacokinetics of intravenous
lignocaine. Eur J Clin Pharmacol 1998; 54:561–5.
177. Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of erythromycin and
itraconazole on the pharmacokinetics of oral lignocaine. Pharmacol
Toxicol 1999; 84:143–6.
178. Scott G, Yih L, Yeh CM, Milosavljev S, Laurent A, Rordorf C. Lu-
miracoxib: pharmacokinetic and pharmacodynamic profile when












1458 • CID 2009:48 (15 May) • REVIEWS OF ANTI-INFECTIVE AGENTS
179. Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ,
Perfect JR. A randomized comparative study to determine the effect
of omeprazole on the peak serum concentration of itraconazole oral
solution. J Antimicrob Chemother 2003; 51:453–7.
180. Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ. Itraconazole mod-
erately increases serum concentrations of oxybutynin but does not
affect those of the active metabolite. Eur J Clin Pharmacol 1997; 52:
403–6.
181. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the
pharmacokinetics and pharmacodynamics of oral prednisolone. Eur
J Clin Pharmacol 2000; 56:57–60.
182. Cato A III, Cao G, Hsu A, Cavanaugh J, Leonard J, Granneman R.
Evaluation of the effect of fluconazole on the pharmacokinetics of
ritonavir. Drug Metab Dispos 1997; 25:1104–6.
183. Koks CH, Crommentuyn KM, Hoetelmans RM, et al. The effect of
fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-
infected individuals. Br J Clin Pharmacol 2001; 51:631–5.
184. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Can-
tarini MV. The effect of fluconazole on the pharmacokinetics of ro-
suvastatin. Eur J Clin Pharmacol 2002; 58:527–31.
185. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Can-
tarini MV. Effect of itraconazole on the pharmacokinetics of rosu-
vastatin. Clin Pharmacol Ther 2003; 73:322–9.
186. Ahonen J, Olkkola KT, Neuvonen PJ. Lack of effect of antimycotic
itraconazole on the pharmacokinetics or pharmacodynamics of tem-
azepam. Ther Drug Monit 1996; 18:124–7.
187. Honig PK, Worham DC, Zamani K, Mullin JC, Conner DP, Cantilena
LR. The effect of fluconazole on the steady-state pharmacokinetics
and electrocardiographic pharmacodynamics of terfenadine in hu-
mans. Clin Pharmacol Ther 1993; 53:630–6.
188. Brockmeyer NH, Tillmann I, Mertins L, Barthel B, Goos M. Phar-
macokinetic interaction of fluconazole and zidovudine in HIV-pos-
itive patients. Eur J Med Res 1997; 2:377–83.
189. Luurila H, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the
pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin
Pharmacol 1998; 54:163–6.
190. Jalava KM, Olkkola KT, Neuvonen PJ. Effect of itraconazole on the
pharmacokinetics and pharmacodynamics of zopiclone. Eur J Clin
Pharmacol 1996; 51:331–4.
191. Ohtani Y, Kotegawa T, Tsutsumi K, Morimoto T, Hirose Y, Nakano
S. Effect of fluconazole on the pharmacokinetics and pharmacody-
namics of oral and rectal bromazepam: an application of electroen-
cephalography as the pharmacodynamic method. J Clin Pharmacol
2002; 42:183–91.
192. Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-
desmethylclozapine are unaffected by the potent CYP3A4 inhibitor
itraconazole. Eur J Clin Pharmacol 1998; 54:167–70.
193. Borin MT, Cox SR, Herman BD, Carel BJ, Anderson RD, Freimuth
WW. Effect of fluconazole on the steady-state pharmacokinetics of
delavirdine in human immunodeficiency virus-positive patients. An-
timicrob Agents Chemother 1997; 41:1892–7.
194. Bruzzese VL, Gillum JG, Israel DS, Johnson GL, Kaplowitz LG, Polk
RE. Effect of fluconazole on pharmacokinetics of 2’,3’-dideoxyinosine
in persons seropositive for human immunodeficiency virus. Anti-
microb Agents Chemother 1995; 39:1050–3.
195. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole does
not affect the steady-state pharmacokinetics of digoxin. Br J Clin
Pharmacol 2003; 56(Suppl 1):45–50.
196. Otsuji Y, Okuyama N, Aoshima T, et al. No effect of itraconazole on
the single oral dose pharmacokinetics and pharmacodynamics of es-
tazolam. Ther Drug Monit 2002; 24:375–8.
197. De Wit S, Debier M, De Smet M, et al. Effect of fluconazole on
indinavir pharmacokinetics in human immunodeficiency virus-in-
fected patients. Antimicrob Agents Chemother 1998; 42:223–7.
198. Purkins L, Wood N, Kleinermans D, Love ER. No clinically significant
pharmacokinetic interactions between voriconazole and indinavir in
healthy volunteers. Br J Clin Pharmacol 2003; 56(Suppl 1):62–8.
199. Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of itraconazole on
the pharmacokinetics of inhaled lidocaine. Basic Clin Pharmacol Tox-
icol 2004; 95:120–3.
200. Ueno K, Yamaguchi R, Tanaka K, et al. Lack of a kinetic interaction
between fluconazole and mexiletine. Eur J Clin Pharmacol 1996; 50:
129–31.
201. Zimmermann T, Yeates RA, Riedel KD, Lach P, Laufen H. The influ-
ence of gastric pH on the pharmacokinetics of fluconazole: the effect
of omeprazole. Int J Clin Pharmacol Ther 1994; 32:491–6.
202. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gem-
fibrozil, itraconazole, and their combination on the pharmacokinetics
of pioglitazone. Clin Pharmacol Ther 2005; 77:404–14.
203. Buchkowsky SS, Partovi N, Ensom MH. Clinical pharmacokinetic
monitoring of itraconazole is warranted in only a subset of patients.
Ther Drug Monit 2005; 27:322–33.
204. Dominguez-Gil HA, Sanchez NA, Garcia Sanchez MJ. Therapeutic
drug monitoring of itraconazole and the relevance of pharmacokinetic
interactions. Clin Microbiol Infect 2006; 12(Suppl 7):97–106.
205. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug
monitoring. Antimicrob Agents Chemother 2006; 50:1570–2.
206. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug
monitoring in allogeneic hematopoietic stem cell transplant recipients.
Bone Marrow Transplant 2005; 35:509–13.
 at K
atholieke U
niversiteit on N
ovem
ber 1, 2012
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
